Krishna Institute Of Medical Sciences Ltd announces a leadership change

The fixed-versus-variable remuneration split cannot be confirmed from the cited record. For KIMS’s CMD and CEO re-appointment resolutions for FY26–FY27, the explanatory-statement material does not disclose a verifiable schedule of:

• fixed salary, allowances, perquisites or other guaranteed benefits;
• variable pay, commission or performance incentives;
• the percentage or monetary weight assigned to fixed and variable components; or
• specific bed-occupancy or ARPOB thresholds, weightings, payout curves or formulae.

Accordingly, the extent to which remuneration is linked to operational KPIs is not established. In particular, no confirmed linkage could be identified between payout and:

• bed occupancy rate;
• ARPOB;
• revenue, EBITDA, PAT or other financial targets; or
• a minimum-performance threshold or cap on variable remuneration.

The correct reading is not that the remuneration is definitively unrelated to occupancy or ARPOB; rather, the specific KPI linkage, if any, could not be confirmed. Without the resolution’s remuneration table or formula, it is not possible to calculate either the fixed/variable mix or the sensitivity of payout to changes in occupancy and ARPOB.

No project-specific mandate or performance covenant tied to the re-appointment could be confirmed. The cited material does not disclose that the re-appointed executive was contractually required to deliver a specified number of beds, facilities, commissioning dates, or capacity milestones in Maharashtra or Karnataka.

The closest strategic commitments reported separately are:

• Maharashtra: expansion is part of the core-market strategy, with the state identified primarily for acquisition-led growth; no Maharashtra-specific bed or facility target is stated. ^[1]
• Karnataka: management intends to pursue a greenfield-led route. The typical hospital format is described as 300–350 beds, with the potential to scale by approximately 100 additional beds. ^[1]
• Karnataka facility pipeline: the annual report says KIMS plans to add three additional facilities in the state, but does not present this as a re-appointment condition or specify a commissioning timetable. ^[2]
• Broader expansion: management said growth would remain focused on Telangana, Andhra Pradesh, Maharashtra, Karnataka and Kerala through greenfield projects, brownfield deals and operating agreements, rather than entry into new geographies. ^[3]

Implication: these are strategic direction statements and operating plans, not explicitly disclosed re-appointment-linked performance milestones. In particular, no cited term sets a Maharashtra capacity target, a Karnataka completion deadline, or a quantified brownfield-versus-greenfield delivery obligation.

Verdict: KIMS has established a long five-year leadership mandate, but the available reappointment filing does not provide enough remuneration detail to assess whether its pay structure is genuinely performance-linked or comparable with peers. The performance-linked incentive-to-fixed-salary ratio is therefore not determinable, rather than demonstrably high or low.

KIMS

• The Board, following the Nomination and Remuneration Committee’s recommendation, approved five-year reappointments for Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as Chairman & Managing Director, and Ms. Dandamudi Anitha as Whole-time Director. The CMD’s continuation beyond age 70 was also approved. ^[4]
• The filing does not state fixed salary, annual performance bonus, commission, stock-based compensation, incentive caps, or performance-weighting methodology. Accordingly, performance-linked incentives / fixed salary = N/D; no reliable ratio can be calculated from the filing. ^[4]
• Dr. Abhinay Bollineni has been CEO since 2019 and is the son of the CMD; the filing also identifies his relationship with another executive director. ^[5] This makes transparent disclosure of independent remuneration benchmarking and objective incentive metrics particularly important from a governance perspective.

Global Health (MEDANTA)

FY26-FY27 remuneration structure, performance-linked incentive ratio, and comparable reappointment-tenure information were not reported in the searched remuneration materials. A peer ratio could not be established.

Narayana Hrudayalaya (NH)

FY26-FY27 fixed salary, variable-pay structure, incentive ratio, and comparable leadership-tenure information were not reported in the searched remuneration materials. A peer ratio could not be established.

Dr. Agarwal’s Health Care

FY26-FY27 remuneration mix, performance-linked incentive ratio, and comparable executive-tenure information were not reported in the searched remuneration materials. A peer ratio could not be established.

Rainbow Children’s Medicare

FY26-FY27 fixed-versus-variable remuneration and comparable reappointment-tenure information were not reported in the searched remuneration materials. A peer ratio could not be established.

Park Medi World

FY26-FY27 remuneration structure, performance-linked incentive ratio, and comparable leadership-tenure information were not reported in the searched remuneration materials. A peer ratio could not be established.

Governance interpretation

KIMS’ five-year terms support continuity and reduce near-term succession disruption, but tenure alone is not evidence of stronger governance. The key missing test is whether a meaningful share of executive compensation is contingent on measurable outcomes such as EBITDA, cash generation, return on capital, quality metrics, patient outcomes, or long-term shareholder value—and whether those metrics have caps, deferral, clawback and independent board oversight.

Therefore, KIMS can be described as strong on disclosed leadership continuity but unproven on pay-for-performance alignment. A like-for-like peer comparison of incentive-to-fixed-salary ratios is not currently possible because the comparable FY26-FY27 remuneration disclosures do not report the necessary inputs.